Skip to content
Open access

Design, Synthesis, Characterization and Pharmacological Evaluation of Novel Imidazole-Based Oxazolone Derivatives as Potential Analgesic and Anti-Inflammatory Agents

Jul 2026 · International journal of chemical and pharmaceutical sciences · Vol 14, pp. 160-164 · 0 citations · 26 references

TL;DR

Most oxazolone derivatives demonstrated dose- and time-dependent analgesic activity, with OXA03, OXA05, OXA07, and OXA09 showing the strongest effects, in some cases comparable to or exceeding standard drugs (indomethacin and diclofenac).

Abstract

The study was undertaken to design, synthesize, characterize, and evaluate novel imidazole-based oxazolone derivatives (OXA01–OXA09) possessing two pharmacophoric systems with the goal of identifying new analgesic and anti-inflammatory lead compounds. A systematic research plan was followed that included molecular design, multi-step organic synthesis, purification, analytical characterization, in vivo pharmacology, in vitro cytotoxicity, and molecular docking. Oxazolone derivatives were synthesized via cyclodehydration of benzoylglycine intermediates with various substituted aryl aldehydes in acetic anhydride–sodium acetate under catalytic ZnO. All intermediates and final compounds were purified and structurally confirmed by TLC, melting point analysis, IR, ¹H/¹³C NMR, LC–MS, and elemental analysis, confirming successful formation of the intended oxazolone scaffolds. Acute oral toxicity studies in rodents revealed no mortality or severe toxic symptoms up to 2560 mg/kg, indicating high safety margins and LD₅₀ greater than 2560 mg/kg, classifying the compounds as low-toxicity agents. Most derivatives demonstrated dose- and time-dependent analgesic activity, with OXA03, OXA05, OXA07, and OXA09 showing the strongest effects, in some cases comparable to or exceeding standard drugs (indomethacin and diclofenac). Compounds such as OXA08 and OXA02 also demonstrated moderate yet meaningful activity.

Read PDF

Similar papers

Open access Sep 2026

Synthesis, characterization, and integrated in silico studies of 4-Aminoantipyrine-derived Schiff bases as promising antimicrobial, antioxidant, and cytotoxic agents: DFT, ADME, and molecular docking studies

The determined biological activities of Schiff base derivatives obtained from 4-aminoantipyrine via condensation with various aromatic and heteroaromatic aldehydes support these derivatives as promising multifunctional scaffolds for the development of novel antibacterial and anticancer agents.

M. I. Sultan, Muthanna C. Urabee, A. Sadiq et al. · 0 citations
Open access Aug 2026

Synthesis, characterization, docking and in vitro evaluation of new pyrazole-carboxylate derivatives as antibacterial, anticancer and anti-inflammatory agents

Mechanistic studies indicated that compounds 5c and 5f inhibited cancer cell growth predominantly by inducing apoptosis rather than cell cycle arrest, indicating favourable selectivity.

Rachel Alveera Menezes, Navas Shereef Ellyan, M. M. et al. · 0 citations
Sep 2026

Synthesis and Computational Evaluation of Substituted Analogues of 4-Sulfonamide Phenylhydrazones as Potential Anticancer Agents: Molecular Docking, Physicochemical Properties, ADME-Tox, and DFT Analysis.

Promising compounds like SBB-2, SBB-3, SBB-5, SBB-6, and SBB-7 exhibit favourable physicochemical properties, high drug-likeness, solubility, and a non-toxic profile, making them strong candidates for further development of a promising drug.

D. Upadhyay, Drashti Thanki, C. Somaiya · 0 citations
Aug 2026

Design, Green Synthesis, DFT Analysis, and Docking Study of Aryl Pyrano-Bis-Coumarin Derivatives as Acetyl Cholinesterase Inhibitors

Abstract This study focuses on the design, green synthesis, and biological evaluation of a series of novel pyrano-bis-coumarin analogs as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. A new saccharin-based ionic liquid, tris(2-hydroxyethyl)ammonium 2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)...

Adile Ayati, Mahnaz Mohammadi, Morteza Zare et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.